Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.15 USD
+0.27 (+5.53%)
Last: 11/26/2025, 8:14:18 PM
5.15 USD
0 (0%)
After Hours: 11/26/2025, 8:14:18 PM
Fundamental Rating

3

Taking everything into account, ABEO scores 3 out of 10 in our fundamental rating. ABEO was compared to 533 industry peers in the Biotechnology industry. While ABEO seems to be doing ok healthwise, there are quite some concerns on its profitability. ABEO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ABEO has reported negative net income.
In the past year ABEO has reported a negative cash flow from operations.
In the past 5 years ABEO always reported negative net income.
ABEO had a negative operating cash flow in each of the past 5 years.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With an excellent Return On Assets value of 35.63%, ABEO belongs to the best of the industry, outperforming 98.69% of the companies in the same industry.
ABEO has a Return On Equity of 48.09%. This is amongst the best in the industry. ABEO outperforms 98.50% of its industry peers.
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With an excellent Profit Margin value of 20587.50%, ABEO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
ABEO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 20587.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
The number of shares outstanding for ABEO has been increased compared to 5 years ago.
Compared to 1 year ago, ABEO has a worse debt to assets ratio.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ABEO has an Altman-Z score of -1.90. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO's Altman-Z score of -1.90 is in line compared to the rest of the industry. ABEO outperforms 52.72% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that ABEO is not too dependend on debt financing.
ABEO's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. ABEO is outperformed by 60.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.9
ROIC/WACCN/A
WACC8.65%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.74 indicates that ABEO has no problem at all paying its short term obligations.
ABEO's Current ratio of 9.74 is amongst the best of the industry. ABEO outperforms 80.49% of its industry peers.
A Quick Ratio of 9.53 indicates that ABEO has no problem at all paying its short term obligations.
ABEO has a better Quick ratio (9.53) than 80.68% of its industry peers.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.53
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.38% over the past year.
The Revenue for ABEO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 27.58% on average over the next years. This is a very strong growth
ABEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 420.09% yearly.
EPS Next Y174.57%
EPS Next 2Y43.89%
EPS Next 3Y38.62%
EPS Next 5Y27.58%
Revenue Next Year27374.5%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
ABEO is valuated quite expensively with a Price/Forward Earnings ratio of 42.08.
Based on the Price/Forward Earnings ratio, ABEO is valued cheaper than 90.24% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.12. ABEO is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 42.08
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ABEO's earnings are expected to grow with 38.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.89%
EPS Next 3Y38.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (11/26/2025, 8:14:18 PM)

After market: 5.15 0 (0%)

5.15

+0.27 (+5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners73.63%
Inst Owner Change0.67%
Ins Owners5.63%
Ins Owner Change-6.45%
Market Cap264.09M
Revenue(TTM)400.00K
Net Income(TTM)82.35M
Analysts86.67
Price Target20.62 (300.39%)
Short Float %22.67%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.03%
Min EPS beat(2)-36.14%
Max EPS beat(2)66.19%
EPS beat(4)3
Avg EPS beat(4)31.61%
Min EPS beat(4)-36.14%
Max EPS beat(4)66.19%
EPS beat(8)4
Avg EPS beat(8)5.48%
EPS beat(12)7
Avg EPS beat(12)27.55%
EPS beat(16)9
Avg EPS beat(16)18.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.39%
PT rev (3m)-1.39%
EPS NQ rev (1m)-253.9%
EPS NQ rev (3m)-249.98%
EPS NY rev (1m)0%
EPS NY rev (3m)1425%
Revenue NQ rev (1m)-56.76%
Revenue NQ rev (3m)-55.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 42.08
P/S 660.23
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)0.12
Fwd EY2.38%
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0.01
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 20587.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 476.46%
Cap/Sales 1857%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.53
Altman-Z -1.9
F-Score6
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)46.91%
Cap/Depr(5y)59.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
EPS Next Y174.57%
EPS Next 2Y43.89%
EPS Next 3Y38.62%
EPS Next 5Y27.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year27374.5%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%
EBIT growth 1Y-36.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-95.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABEONA THERAPEUTICS INC / ABEO FAQ

Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ABEO.


What is the valuation status for ABEO stock?

ChartMill assigns a valuation rating of 3 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.


Can you provide the profitability details for ABEONA THERAPEUTICS INC?

ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.